The main goal of this study is to see if the study drug called "Deucravacitinib" is safe and
effective in treating people with pyoderma gangrenosum (PG).
The main goal of this study is to see if the study drug called "Deucravacitinib" is safe and
effective in treating people with pyoderma gangrenosum (PG).
Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).
Recruiting
Bristol-Myers Squibb
Phase 2
2023-11-30
The study is a randomized, proof of concept study. 30 patients aged 18 and over with HS will
be included in this single center, randomized, double-blind, parallel-group study. Dosage of
deucravacitinib will be given according to the investigational regimen as follows: 6 mg po
bid for 16 weeks. The study compromises a 4-week screening period, a 16-week study period,
and a 4-week follow-up period. The follow-up period consists of a follow-up phone call 4
weeks after the last study drug dose.
Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).
Recruiting
Beth Israel Deaconess Medical Center
Phase 2
2023-11-30
The study is a randomized, proof of concept study. 30 patients aged 18 and over with HS will
be included in this single center, randomized, double-blind, parallel-group study. Dosage of
deucravacitinib will be given according to the investigational regimen as follows: 6 mg po
bid for 16 weeks. The study compromises a 4-week screening period, a 16-week study period,
and a 4-week follow-up period. The follow-up period consists of a follow-up phone call 4
weeks after the last study drug dose.
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis
Recruiting
Bristol-Myers Squibb
Phase 4
2023-10-10
The purpose of this study is to measure the safety and effectiveness of deucravatinib in
participants with non-pustular palmoplantar psoriasis and genital psoriasis.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
